Document Detail


Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
MedLine Citation:
PMID:  7929271     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP) binds several ligands, including complex between the two chain urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1), and the single chain zymogen pro-urokinase (pro-uPA). We have used truncated variants of uPA and PAI-1 as well as Fab fragments of monoclonal antibodies with known epitopes to identify regions in the uPA.PAI-1 complex and in pro-uPA involved in binding to alpha 2MR/LRP.uPA.PAI-1 complex bound with high affinity (EC50 about 0.4 nM) via contacts in the PAI-1 moiety as well as the uPA serine proteinase domain and the uPAA chain. Pro-uPA bound with lower affinity (EC50 about 10 nM), and efficient binding to alpha 2MR/LRP was dependent on contact with both the A chain and the serine proteinase domain. We analyzed the effect of complex formation with the urokinase receptor since this is the primary target for binding of uPA.PAI-1 and pro-uPA at the cell surface, and since it has been demonstrated that urokinase receptor-bound uPA.PAI-1 complex is internalized following interaction with alpha 2 MR/LRP (Nykjaer, A., Petersen, C. M., Møller, B., Jensen, P.H., Moestrup, S.K., Holtet, T.L., Etzerodt M., Thøgersen, H.C., Munch, M., Andreasen, P.A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546). Soluble recombinant urokinase receptor blocked the binding of pro-uPA to alpha 2MR/LRP but caused only a slight reduction in the affinity for binding of uPA.PAI-1. Moreover, pro-uPA bound to the urokinase receptor at the cell surface was not internalized and degraded unless activated to uPA and complexed with PAI-1. We conclude that pro-uPA is protected against degradation via alpha 2MR/LRP when bound to uPAR due to shielding of a binding contact in the A chain, whereas the affinity of uPAR-bound uPA.PAI-1 complex for binding to alpha 2MR/LRP remains sufficient to allow rapid internalization and degradation.
Authors:
A Nykjaer; L Kjøller; R L Cohen; D A Lawrence; B A Garni-Wagner; R F Todd; A J van Zonneveld; J Gliemann; P A Andreasen
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  269     ISSN:  0021-9258     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  1994 Oct 
Date Detail:
Created Date:  1994-11-17     Completed Date:  1994-11-17     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  25668-76     Citation Subset:  IM    
Affiliation:
Department of Medical Biochemistry, University of Aarhus, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3T3 Cells
Animals
Antibodies, Monoclonal
Endocytosis / physiology*
Enzyme Precursors / metabolism*
Humans
Immunoglobulin Fab Fragments
LDL-Receptor Related Protein 1
Mice
Models, Biological
Plasminogen Activator Inhibitor 1 / immunology,  metabolism*
Plasminogen Activators / metabolism
Protein Binding
Receptors, Cell Surface / metabolism
Receptors, Immunologic / metabolism*
Receptors, LDL / metabolism*
Receptors, Urokinase Plasminogen Activator
Recombinant Proteins / immunology,  metabolism
Structure-Activity Relationship
Urokinase-Type Plasminogen Activator / immunology,  metabolism*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Enzyme Precursors; 0/Immunoglobulin Fab Fragments; 0/LDL-Receptor Related Protein 1; 0/PLAUR protein, human; 0/Plasminogen Activator Inhibitor 1; 0/Plaur protein, mouse; 0/Receptors, Cell Surface; 0/Receptors, Immunologic; 0/Receptors, LDL; 0/Receptors, Urokinase Plasminogen Activator; 0/Recombinant Proteins; 99149-95-8/saruplase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulat...
Next Document:  Molecular cloning and chromosome localization of a putative basolateral Na(+)-K(+)-2Cl- cotransporte...